Please assess the completion status of the following clinical trial:

Trial Title: S-1 and Photodynamic Therapy in Cholangiocarcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic or cytologic diagnosis of cholangiocarcinoma~* Not eligible for curative surgery~* Eastern Cooperative Oncology Group (ECOG) performance status of 2 or better~* No serious or uncontrolled concomitant medical illness~* Adequate bone marrow function (absolute neutrophil count ≧1,500 ul, platelet count ≧75,000/ul)~* Consent this study in letter~Exclusion Criteria:~* Another neoplasia~* Porphyria~* Pregnant or breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Treatment by combination of photodynamic therapy and S-1~1. PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation~2. S-1 chemotherapy before intolerable complication or definite tumor progression Based on the body surface area, \<1.25m2: 80mg/day, 1.25\~1.5m2: 100mg/day, ≧1.5m2: 120mg/day Given orally twice daily for 14days, followed by 7 days without treatment
- 2 (Type: ACTIVE_COMPARATOR): Treatment by photodynamic therapy only~1. PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation~2. Other managements except systemic chemotherapy were added freely.
- 3 (Type: OTHER): Treatment by photodynamic therapy only or combined chemotherapy with photodynamic therapy: Open label

Based on this trial design, predict the completion outcome and termination type (if applicable).